RARanan Gulhan Aktas

Ranan Gulhan Aktas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ranan Gulhan Aktas has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-Term Characteristics of Human-Derived Biliary Organoids under a Single Continuous Culture Condition

    by Ranan G. Aktas, Michael Karski, Biju Issac, Liang Sun, Shira Rockowitz, Piotr Sliz, Khashayar Vakili

    Organoids have been used to investigate the three-dimensional (3D) organization and function of their respective organs. These self-organizing 3D structures offer a distinct advantage over traditional two-dimensional (2D) culture techniques by creating a more physiologically relevant milieu to study complex biological systems. The goal of this study was to determine the feasibility of establishing organoids from various pediatric liver diseases and characterize the long-term evolution of cholangiocyte organoids (chol-orgs) under a single continuous culture condition. We established chol-orgs from 10 different liver conditions and characterized their multicellular organization into complex epithelial structures through budding, merging, and lumen formation. Immunofluorescent staining, electron microscopy, and single-nucleus RNA (snRNA-seq) sequencing confirmed the cholangiocytic nature of the chol-orgs. There were significant cell population differences in the transcript profiles of two-dimensional and organoid cultures based on snRNA-seq. Our study provides an approach for the generation and long-term maintenance of chol-orgs from various pediatric liver diseases under a single continuous culture condition.


  • LC–MS/MS analysis, antioxidant and anticancer effects of phenolic-rich extracts from Algerian propolis: a comparative study

    by Safia Boulechfar, Zeynep Akbulut, Hafize Dilek Tepe, Amar Zellagui, Ranan Gulhan Aktas, Chawki Bensouici, Fatma Doyuk, Latifa Khattabi, Gamze Demirel, Mesbah Lahouel


  • Open Access

    Low-dose cisplatin exposure and SNAIL, Vimentin, E-cadherin expression in HEPG2 cell line

    by Yaprak Dönmez Çakıl, Zeynep Akbulut, Ranan Gülhan Aktaş, Zeynep Gunes Ozunal

    Cisplatin, the first platinum compound approved for cancer treatment, is widely used in the treatment of various cancers including hepatocellular carcinoma (HCC). HCC incidence rates rise globally. Epithelial mesenchymal transition (EMT) is implicated in cancer invasion and metastasis, which are associated with increased mortality. Cisplatin dose might influence cancer invasion and metastatic behavior of the cells. The aim of the study was to investigate the effect of low-dose cisplatin treatment on EMT- related changes in HepG2 cells. Following treatment with 4 µM cisplatin, HepG2 cells were evaluated morphologically. Gene expression of E-cadherin, Vimentin, Snail1 was assessed by quantitative PCR. Immunofluorescence analyses of NA-K ATPase were performed. Although the low-dose cisplatin treated cells exhibited a more stretched morphology, no statistical difference was detected in gene expression of E-cadherin, Vimentin, Snail1 and immunofluorescence of NA-K ATPase. Findings on low-dose cisplatin effects in HepG2 might contribute to the knowledge of antineoplastic inefficacy by further understanding the molecular mechanisms of drug action.


  • Open Access

    Morphological and biochemical effects of carnosic acid on human hepatocellular carcinoma HepG2 cells

    by Askin Keskin Kaplan, Hatice Maras, Merve Dilara Kolsan, Mustafa Erinç Sitar, Ranan Gülhan Aktaş

    Antecedentes / objetivo : La muerte celular autofágica y la apoptosis de células tumorales se ha convertido en uno de los principales objetivos en el tratamiento del cáncer, mientras que las líneas celulares tumorales se utilizan principalmente en estudios para proporcionar datos importantes para la evaluación de posibles sustancias anticancerígenas. En este estudio, nuestro objetivo fue evaluar los cambios morfológicos y bioquímicos, incluida la tasa de apoptosis y los niveles de alfa fetoproteína (AFP) a diferentes concentraciones de ácido carnósico (CA) en células de carcinoma hepatocelular humano HepG2. Materiales y métodos : Carcinoma hepatocelular humano (células HepG2 de séptimo pase) .Las líneas celulares se cultivaron en cubreobjetos de vidrio Schott D263M de 11 µM colocados en placas de 12 pocillos y se trataron con DMSO, concentraciones de CA 1, 2,5, 5 y 10 µM durante 24 horas. 48 y 72 horas. Los datos morfológicos y bioquímicos se registraron diariamente, incluidas las tasas de apoptosis demostradas por Caspasa 3, las expresiones de Anexina V bajo luz invertida y microscopía de inmunofluorescencia, luego se analizaron los datos para determinar la significación estadística. Los niveles de AFP, albúmina y proteínas totales se analizaron espectrofotométricamente para evaluación bioquímica. Resultados : Nuestros resultados mostraron que CA inhibió significativamente la proliferación de células HepG2 de una manera dependiente de la dosis y el tiempo y causó significativamente la formación de vacuolas autofágicas comenzando desde 5 µM y alcanzando significancia a concentraciones de 10 µM. Se observó una disminución significativa en la AFP cuando se examinaron las expresiones de 48 y 72 horas, alcanzando el nivel más bajo a las 72 horas en el grupo de CA 10 µM. Además, el aumento en los niveles de albúmina alcanzó significación solo en el grupo de 48 h, mientras que también se observaron aumentos no significativos en los grupos de 24 hy 72 h. Conclusión: Nuestro estudio actual demuestra un aumento significativo en las tasas de apoptosis por el ácido carnósico principalmente a concentraciones de 10 µM, lo que respalda su efecto anticancerígeno en las células HepG2. Estos hallazgos también están respaldados por cambios en los análisis bioquímicos de los niveles de albúmina y AFP a concentraciones de 10 µM.


  • Open Access

    The expression of CD44, CD90 and CD133 in response to cisplatin in hepatocellular cancer cells

    by Yaprak Donmez Cakıl, Zeynep Gunes Ozunal, Damla Gokceoglu Kayalı, Ranan Gulhan Aktas

    Introduction. Cancer is a leading cause of mortality. Hepatocellular cancer is one of the malignancies associated with poor outcome and resistance to pharmacotherapy. Cancer stem cells (CSCs) contribute to resistance to therapy and hence lead to the treatment failure of tumors. Aim. This study aims to explore the expression of CSCs in response to cisplatin treatment in HepG2 hepatocellular cancer cell line. Material and methods. Cell proliferation test, CCK-8, was used to evaluate the cell proliferation following cisplatin treatment for 72 hours. The expressions of CSC markers CD44, CD90, and CD133 were assessed by flow cytometric analysis. Results. The results showed a dose-dependent decrease in cell proliferation and increased expression of CSC markers CD44 and CD90 in response to cisplatin. Conclusion. Understanding the roles of CSC markers may point to new targets and therapeutic strategies to predict and overcome cisplatin resistance.


  • Open Access

    LIVER CANCER STEM CELLS

    by Ranan Aktas

    Recent studies have shown that many tumours are containing small population of stem cell-like cells, in other words, cancer stem cells. The rapid development of the cancer stem cell field has allowed the scientists and the clinicians to focus on another challenge, which targets cancer stem cells for new therapeutic strategies. Studies showed that novel therapeutic approaches on the selective targeting of cancer stem cells might be extremely successful for prevention of invasion, metastasis, and the relapses of tumors. Liver cancer is the 5th most common cancer type. It has also been reported as the third most common cause of cancer related death. Recently, progression of hepatocellular carcinoma is thought to be driven by cancer stem cells. There are tremendous efforts to clarify the features of liver cancer stem cells, to identify them within other tumor cells, and finally to develop the new therapeutic models that target those cells. This review summarizes the features of liver cancer stem cells, and its importance for therapeutic approaches.